Dr. Michael David Mello, MD

Dr. Mello practices at USC Verdugo Hills Ambulatory Surgery Center in Glendale, California.

Dr. Mello's NPI, 1356571566, was assigned on July 22, 2009. Dr. Mello graduated from Keck School of Medicine of USC in 2009. Dr. Mello holds California license A135756.

Dr. Mello's primary practice is USC Verdugo Hills Ambulatory Surgery Center, at 1818 Verdugo Blvd Ste B1, Glendale, CA 91208. The practice phone is (213) 740-7922.

Dr. Mello's primary practice is USC Verdugo Hills Ambulatory Surgery Center in Glendale, California. Dr. Mello is also affiliated with USC Verdugo Hills Hospital. Dmand AI also links Dr. Mello to 1 more hospital and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mello practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Mello's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Mello is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Mello's licenses on file in 2 states: California and Missouri.

Dmand AI lists colonoscopy, esophagus, stomach, or upper small intestine surgery, gastroenteritis, gastrointestinal bleeding, hemorrhoids, intestinal diverticulosis, irritable bowel syndrome (IBS) and pancreas or bile duct endoscopy (ERCP) among the conditions Dr. Mello treats.

CMS data shows 1,232 Medicare services from Dr. Mello across 19 procedure codes in 2024, for 614 Medicare patients. Medicare paid $126,495 for them.

CMS counts 614 Medicare patients who saw Dr. Mello in 2024. The largest group is 65 to 74, with 237 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 62% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mello's median patient age at 61, with 51% women.

In 2024, Dr. Mello wrote 1,012 Medicare Part D claims for 561 patients. 87% of them were for generic drugs. CMS names the drug for 861 of them, across 18 drugs with 11 or more claims each, at $83,829 in total drug cost. In 2023, CMS named 784 claims across 17 drugs.

Dr. Mello accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mello as offering telehealth. CMS counts 495 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Mello, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Mello, published from 2012 to 2020. 2016 was the busiest year, with 2. The most frequent topics are Manometry, Gastroesophageal Reflux and Esophageal Achalasia. Dr. Mello has published most often in Neurogastroenterol Motil. Dr. Mello's most frequent co-authors are Chandra Prakash Gyawali, MD, Amy Rubin Shriver, MD and Adil Abubaker Abdalla, MD.

CMS Open Payments shows 32 general payments to Dr. Mello from 8 drug and device companies from 2016 to 2025. Grants make up the largest share, 94% of the total. Boston Scientific Corporation paid the most, $10,038.

Dr. Mello graduated from Keck School of Medicine of USC in 2009.

Dr. Mello is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.